Acute anticonvulsant effects of capric acid in seizure tests in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 57, Issue , 2015, Pages 110-116

  Wlaź, Piotr ^a   Socała, Katarzyna ^a   Nieoczym, Dorota ^a   Zarnowski, Tomasz ^b   Zarnowska, Iwona ^b   Czuczwar, Stanisław J ^b   Gasior, Maciej ^c  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

6 Hz seizure test; Ketogenic diet; Maximal electroshock; Medium chain fatty acids; Pentylenetetrazole; Seizure thresholds test

Indexed keywords

3 HYDROXYBUTYRIC ACID; DECANOIC ACID; GLUCOSE; OCTANOIC ACID; PENTETRAZOLE; ANTICONVULSIVE AGENT; DECANOIC ACID DERIVATIVE; GLUCOSE BLOOD LEVEL; OCTANOIC ACID DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHIMNEY TEST; CONTROLLED STUDY; CONVULSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG EXPOSURE; GRIP STRENGTH; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; SEIZURE; SEIZURE THRESHOLD; ANIMAL; BLOOD; BRAIN; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; METABOLISM; PH; SEIZURES;

3-HYDROXYBUTYRIC ACID; ANIMALS; ANTICONVULSANTS; BLOOD GLUCOSE; BRAIN; CAPRYLATES; DECANOIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HYDROGEN-ION CONCENTRATION; MALE; MICE; MOTOR SKILLS; SEIZURES;

EID: 84911441209     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.10.013     Document Type: Article

References (68)

1. Bach A.C., Babayan V.K. Medium-chain triglycerides: an update. Am J Clin Nutr 1982, 36:950-962.
2. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001, 47:217-227.
3. Caraballo R.H., Vining E. Ketogenic diet. Handb Clin Neurol 2012, 108:783-793.
4. Chang P., Terbach N., Plant N., Chen P.E., Walker M.C., Williams R.S.B. Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 2013, 69:105-114.
5. Cullingford T. Peroxisome proliferator-activated receptor alpha and the ketogenic diet. Epilepsia 2008, 49(Suppl. 8):70-72.
6. Dahl D.R., Dahl N., Samson F.E. A study on the narcotic action of the short chain fatty acids. J Clin Invest 1956, 35:1291-1298.
7. Danial N.N., Hartman A.L., Stafstrom C.E., Thio L.L. How does the ketogenic diet work? Four potential mechanisms. J Child Neurol 2013, 28:1027-1033.
8. Del Vecchio G., Tscheik C., Tenz K., Helms H.C., Winkler L., Blasig R., et al. Sodium caprate transiently opens claudin-5-containing barriers at tight junctions of epithelial and endothelial cells. Mol Pharm 2012, 9:2523-2533.
9. Ebert D., Haller R.G., Walton M.E. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci 2003, 23:5928-5935.
10. Edmond J., Higa T.A., Korsak R.A., Bergner E.A., Lee W.N. Fatty acid transport and utilization for the developing brain. J Neurochem 1998, 70:1227-1234.
11. Freeman J.M., Kossoff E.H., Hartman A.L. The ketogenic diet: one decade later. Pediatrics 2007, 119:535-543.
12. Gasior M., Rogawski M.A., Hartman A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 2006, 17:431-439.
13. Gasior M., French A., Joy M.T., Tang R.S., Hartman A.L., Rogawski M.A. The anticonvulsant activity of acetone, the major ketone body in the ketogenic diet, is not dependent on its metabolites acetol, 1,2-propanediol, methylglyoxal, or pyruvic acid. Epilepsia 2007, 48:793-800.
14. Gasior M., Socala K., Nieoczym D., Wlaz P. Clavulanic acid does not affect convulsions in acute seizure tests in mice. J Neural Transm 2012, 119:1-6.
15. Giardina W.J., Gasior M. Acute seizure tests in epilepsy research: electroshock- and chemical-induced convulsions in the mouse. Curr Protoc Pharmacol 2009, 45:5.22.1-5.22.37.
16. Haidukewych D., Forsythe W.I., Sills M. Monitoring octanoic and decanoic acids in plasma from children with intractable epilepsy treated with medium-chain triglyceride diet. Clin Chem 1982, 28:642-645.
17. Hartman A.L., Vining E.P. Clinical aspects of the ketogenic diet. Epilepsia 2007, 48:31-42.
18. Hartman A.L., Gasior M., Vining E.P., Rogawski M.A. The neuropharmacology of the ketogenic diet. Pediatr Neurol 2007, 36:281-292.
19. Hartman A.L., Lyle M., Rogawski M.A., Gasior M. Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia 2008, 49:334-339.
20. Henderson S.T. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 2008, 5:470-480.
21. Hughes S.D., Kanabus M., Anderson G., Hargreaves I.P., Rutherford T., O'Donnell M., et al. The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem 2014, 129:426-433.
22. Huttenlocher P.R., Wilbourn A.J., Signore J.M. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 1971, 21:1097-1103.
23. Jeong E.A., Jeon B.T., Shin H.J., Kim N., Lee D.H., Kim H.J., et al. Ketogenic diet-induced peroxisome proliferator-activated receptor-gamma activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures. Exp Neurol 2011, 232:195-202.
24. Jiang W., Van C.J., Sheerin A.H., Ji S.P., Zhang Y., Saucier D.M., et al. Involvement of extracellular regulated kinase and p38 kinase in hippocampal seizure tolerance. J Neurosci Res 2005, 81:581-588.
25. Johnson R.C., Young S.K., Cotter R., Lin L., Rowe W.B. Medium-chain-triglyceride lipid emulsion: metabolism and tissue distribution. Am J Clin Nutr 1990, 52:502-508.
26. Juge N., Gray J.A., Omote H., Miyaji T., Inoue T., Hara C., et al. Metabolic control of vesicular glutamate transport and release. Neuron 2010, 68:99-112.
27. Jung S., Bullis J.B., Lau I.H., Jones T.D., Warner L.N., Poolos N.P. Downregulation of dendritic HCN channel gating in epilepsy is mediated by altered phosphorylation signaling. J Neurosci 2010, 30:6678-6688.
28. Kamata Y., Shiraga H., Tai A., Kawamoto Y., Gohda E. Induction of neurite outgrowth in PC12 cells by the medium-chain fatty acid octanoic acid. Neuroscience 2007, 146:1073-1081.
29. Kimball A.W., Burnett W.T., Doherty D.G. Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice. Radiat Res 1957, 7:1-12.
30. Kossoff E.H., Rho J.M. Ketogenic diets: evidence for short- and long-term efficacy. Neurotherapeutics 2009, 6:406-414.
31. Likhodii S.S., Serbanescu I., Cortez M.A., Murphy P., Snead O.C., Burnham W.M. Anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet. Ann Neurol 2003, 54:219-226.
32. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949, 96:99-113.
33. Liu M.J., Pollack G.M. Pharmacokinetics and pharmacodynamics of valproate analogues in rats. IV. Anticonvulsant action and neurotoxicity of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid. Epilepsia 1994, 35:234-243.
34. Liu Y.M., Wang H.S. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biomed J 2013, 36:9-15.
35. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011, 20:359-368.
36. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 1991, 8:79-94.
37. Malapaka R.R., Khoo S., Zhang J., Choi J.H., Zhou X.E., Xu Y., et al. Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem 2012, 287:183-195.
38. Masino S.A., Rho J.M. Mechanisms of ketogenic diet action. Jasper's basic mechanisms of the epilepsies [Internet] 2012, National Center for Biotechnology Information (US), Bethesda (MD). 4th ed. M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta, J.L. Noebels (Eds.).
39. McGarry J.D., Foster D.W. The regulation of ketogenesis from octanoic acid. The role of the tricarboxylic acid cycle and fatty acid synthesis. J Biol Chem 1971, 246:1149-1159.
40. Miranda M.J., Turner Z., Magrath G. Alternative diets to the classical ketogenic diet-can we be more liberal?. Epilepsy Res 2012, 100:278-285.
41. Mitkov D., Toreva D. A study on the comatose action of short chain fatty acids. Folia Med (Plovdiv) 1979, 21:20-25.
42. Nakamura J., Miwa T., Sasaki H., Shibasaki J., Kaneto H. Effect of straight chain fatty acids on seizures induced by picrotoxin and pentylenetetrazole in mice. J Pharmacobiodyn 1990, 13:76-81.
43. Neal E.G., Chaffe H., Schwartz R.H., Lawson M.S., Edwards N., Fitzsimmons G., et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia 2009, 50:1109-1117.
44. Nieoczym D., Luszczki J.J., Czuczwar S.J., Wlaz P. Effect of sildenafil on the anticonvulsant action of classical and second-generation antiepileptic drugs in maximal electroshock-induced seizures in mice. Epilepsia 2010, 51:1552-1559.
45. Ohnishi T., Aida K., Awazu S. Enhancement of blood-brain barrier permeability by sodium caprate. J Pharm Pharmacol 1999, 51:1015-1018.
46. Papamandjaris A.A., MacDougall D.E., Jones P.J. Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications. Life Sci 1998, 62:1203-1215.
47. Pellmar T.C. Fatty acids modulate excitability in guinea-pig hippocampal slices. Neuroscience 1991, 45:273-280.
48. Perlman B.J., Goldstein D.B. Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids. Mol Pharmacol 1984, 26:83-89.
49. Porta N., Vallee L., Lecointe C., Bouchaert E., Staels B., Bordet R., et al. Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties. Epilepsia 2009, 50:943-948.
50. Porter R.J., Dhir A., Macdonald R.L., Rogawski M.A. Mechanisms of action of antiseizure drugs. Handb Clin Neurol 2012, 108:663-681.
51. Preston E., Slinn J., Vinokourov I., Stanimirovic D. Graded reversible opening of the rat blood-brain barrier by intracarotid infusion of sodium caprate. J Neurosci Methods 2008, 168:443-449.
52. Puligheddu M., Pillolla G., Melis M., Lecca S., Marrosu F., De Montis M.G., et al. PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings. PLoS One 2013, 8:e64541.
53. Rapoport S.I. In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci 2001, 16:243-261.
54. Rho J.M., Anderson G.D., Donevan S.D., White H.S. Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia 2002, 43:358-361.
55. Sills M.A., Forsythe W.I., Haidukewych D. Role of octanoic and decanoic acids in the control of seizures. Arch Dis Child 1986, 61:1173-1177.
56. Sills M.A., Forsythe W.I., Haidukewych D., Macdonald A., Robinson M. The medium chain triglyceride diet and intractable epilepsy. Arch Dis Child 1986, 61:1168-1172.
57. Smith M., Wilcox K.S., White H.S. Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4:12-17.
58. Spector R. Fatty acid transport through the blood-brain barrier. J Neurochem 1988, 50:639-643.
59. Stafstrom C.E., Rho J.M. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol 2012, 3:1-8.
60. Than K.D., Kossoff E.H., Rubenstein J.E., Pyzik P.L., McGrogan J.R., Vining E.P. Can you predict an immediate, complete, and sustained response to the ketogenic diet?. Epilepsia 2005, 46:580-582.
61. Traul K.A., Driedger A., Ingle D.L., Nakhasi D. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol 2000, 38:79-98.
62. Walker C.O., McCandless D.W., McGarry J.D., Schenker S. Cerebral energy metabolism in short-chain fatty acid-induced coma. J Lab Clin Med 1970, 76:569-583.
63. Wilder R.M. The effects of ketonemia on the course of epilepsy. Mayo Clin Proc 1921, 2:307-308.
64. Wlaz P., Löscher W. Evaluation of associated behavioral and cognitive deficits in anticonvulsant drug testing. Neuropharmacology methods in epilepsy research 1998, 171-192. CRC Press, Boca Raton. S.L. Peterson, T.E. Albertson (Eds.).
65. Wlaz P., Socala K., Nieoczym D., Luszczki J.J., Zarnowska I., Zarnowski T., et al. Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology 2012, 62:1882-1889.
66. Yonekawa W.D., Kupferberg H.J., Woodbury D.M. Relationship between pentylenetetrazol-induced seizures and brain pentylenetetrazol levels in mice. J Pharmacol Exp Ther 1980, 214:589-593.
67. Zarnowska I., Luszczki J.J., Zarnowski T., Buszewicz G., Madro R., Czuczwar S.J., et al. Pharmacodynamic and pharmacokinetic interactions between common antiepileptic drugs and acetone, the chief anticonvulsant ketone body elevated in the ketogenic diet in mice. Epilepsia 2009, 50:1132-1140.
68. Zhao W., Varghese M., Vempati P., Dzhun A., Cheng A., Wang J., et al. Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PLoS One 2012, 7:e49191.